Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ocuvers Lipostamin is a liposomal spray developed by Innomedis AG for the treatment of dry eye syndrome (DES). It is formulated with a phospholipid complex and a blend of natural plant extracts, including *Capparis spinosa* (caper), *Helichrysum italicum* (everlasting), *Euphrasia officinalis* (eyebright), and *Glycyrrhiza glabra* (licorice). The spray is designed to stabilize the lipid layer of the tear film, which is often deficient in patients with dry eye. Clinical studies suggest that Ocuvers Lipostamin effectively improves subjective comfort, tear break-up time (TBUT), and tear meniscus height, while also reducing conjunctival redness, potentially due to the anti-inflammatory and antioxidant properties of its botanical components. It is noted for having a better tolerability profile, including less initial burning sensation and a less fatty smell, compared to earlier generations of liposomal sprays.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ocuvers Lipostamin.